Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 14 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung CancerNot yet recruitingNCT05994339Phase 2/3
- IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCRecruitingNCT05994131Phase 1/2
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
- A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)RecruitingNCT05989542Phase 3
- Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid CancerRecruitingNCT05989425Phase 2
- Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLCRecruitingNCT05987826Phase 2
- A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT05976763Phase 3
- Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular CarcinomaRecruitingNCT05971199Phase 2
- Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GISTNot yet recruitingNCT05970900Phase 3
- Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusRecruitingNCT05969496Phase 2
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic CancerRecruitingNCT05969171Phase 2
- A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.RecruitingNCT05967689Phase 2
- Go-CHOP as the Frontline Therapy for PTCLRecruitingNCT05963347Phase 2
- Effect of JAK Inhibitor on Erosion Healing in RARecruitingNCT05955066Phase 4
- A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyRecruitingNCT05954429Phase 2
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 2
- A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLRecruitingNCT05950997Not applicable
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
- TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesRecruitingNCT05948813Phase 2
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingNCT05947851Phase 3
- Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.RecruitingNCT05946460Phase 2
- Bioequivalence Studies of Dasatinib 100 MgNot yet recruitingNCT05944783Phase 4
- Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT05943496Phase 1
- A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and ChemotherapyRecruitingNCT05942508Phase 1
- Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
- Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT05935579Phase 2
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell LymphomaRecruitingNCT05933967Phase 2
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingNCT05933395Phase 2
- Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune ThrombocytopeniaRecruitingNCT05932524Phase 2
- Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
- A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALLNot yet recruitingNCT05931757Phase 2
- Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)RecruitingNCT05931393Phase 2
- A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in OsteosarcomaRecruitingNCT05926492Phase 2
- Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRecruitingNCT05926427Phase 2
- Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05924997Phase 1/2
- Zanubrutinib in the Treatment of Relapsed/Refractory wAIHARecruitingNCT05922839Phase 2
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
- Ruxolitinib as GVHD Prophylaxis in AA PatientsNot yet recruitingNCT05914714Phase 2
- Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
- Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric CancerNot yet recruitingNCT05914610Phase 3
- "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.Not yet recruitingNCT05914584Phase 2/3
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Phase 2
- Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast CancerRecruitingNCT05910398Phase 3
- Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal TumorRecruitingNCT05905887Phase 2
- A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerRecruitingNCT05904457Phase 2
- Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseaseRecruitingNCT05904093Phase 1
- Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyRecruitingNCT05903833Phase 2
- Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05903456Phase 2
- Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingNCT05900089Phase 1
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
- A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCRecruitingNCT05896059Phase 2
- Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCTRecruitingNCT05896007Phase 2
- Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver MetastasesNot yet recruitingNCT05894837Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)RecruitingNCT05893056Phase 2
- Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsNot yet recruitingNCT05887726Phase 2
- Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT05882630Phase 1/2
- c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene AberrationRecruitingNCT05882292Phase 2
- Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast CancerRecruitingNCT05880927Phase 2
- A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)Not yet recruitingNCT05876832Phase 3
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeRecruitingNCT05873712Phase 2
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 2
- Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKIRecruitingNCT05869162Phase 2
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative ColitisRecruitingNCT05867329Phase 4
- Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerRecruitingNCT05866510Phase 2
- Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionRecruitingNCT05865132Phase 2
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Phase 3
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingNCT05862285Phase 3
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerRecruitingNCT05861271Phase 2
- A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)Not yet recruitingNCT05859217Phase 2
- Correction of Psoriatic T Cell Signatures by DeucravacitinibRecruitingNCT05858645Phase 4
- Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCRecruitingNCT05854849Phase 3
- Inflammation and Depression in People With HIVRecruitingNCT05849038Phase 2
- Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's SyndromeRecruitingNCT05845723Phase 2
- Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal SarcomaEnrolling by invitationNCT05844813Phase 4
- Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCRecruitingNCT05842317Phase 1/2
- Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
- Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast CancerNot yet recruitingNCT05841381Phase 3
- The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue SarcomaRecruitingNCT05839275Phase 1/2
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCCRecruitingNCT05839197Phase 2
- Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)RecruitingNCT05835245Phase 2
- Pyrotinib in Women With High-risk in Early Stage Breast CancerRecruitingNCT05834764Phase 2
- A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.RecruitingNCT05833763Phase 2
- Study of Anlotinib in Patients With Advanced Medullary Thyroid CarcinomaRecruitingNCT05830500Phase 4
- IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerRecruitingNCT05827796Phase 1/2
- Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast CancerRecruitingNCT05823623Phase 2
- Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaRecruitingNCT05823311Phase 3
- Avapritinib in CBF-AML With KIT MutationsRecruitingNCT05821738Phase 2
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaRecruitingNCT05820841Phase 3
- To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCRecruitingNCT05818982Phase 2
- Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)RecruitingNCT05818267Not applicable
- Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPNRecruitingNCT05817955Phase 2
- Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsRecruitingNCT05817903Phase 2
- Cadonilimab Plus Anlotinib for R/M/P Cervical CancerRecruitingNCT05817214Phase 2
- Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLCEnrolling by invitationNCT05813522Phase 2
- Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT05812430Phase 2
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
- Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2
- Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingNCT05800275Phase 2